Navigation Links
Using bone marrow to protect the brain
Date:9/19/2011

The ability to produce neuroprotectors, proteins that protect the human brain against neurodegenerative disorders such as Parkinson's and ALS, is the holy grail of brain research. A technology developed at Tel Aviv University does just that, and it's now out of the lab and in hospitals to begin clinical trials with patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

Developed by Prof. Daniel Offen and Prof. Eldad Melamed of TAU's Sackler Faculty of Medicine and Felsenstein Medical Research Center, the technology is now a patent-pending process that takes stem cells from a patient's own bone marrow and causes them to differentiate into astrocyte-like cells, which are responsible for the well-being of the brain's neurons. The cells release neurotrophic factors, or neuroprotectants, which have been shown to play a key role in reducing the progress of ALS, a debilitating disease characterized by the progressive degeneration of motor neurons, resulting in paralysis of a patient's limbs and organ function.

The research has appeared in the Journal of Stem Cells Reviews and Reports and a number of other publications.

Trials in Jerusalem and Boston

This stem cell technology, says Prof. Offen, represents 10 years of development. Inspired by advances in embryonic stem cell research and its huge potential but trying to bypass the ethical and safety issues Prof. Offen and his fellow researchers turned to stem cells derived from a patient's own bone marrow.

After coaxing the cells to differentiate into astrocyte-like cells, whose natural function is to guard the brain's neurons and prevent deterioration, the researchers began testing the concept in animal models. "In the mouse model," Prof. Offen explains, "we were able to show that the bone marrow derived stem cells prevent degeneration in the brain following injection of selective neurotoxins." Researchers also demonstrated that transplantation of these cells increased the survival rate in the mouse model of ALS and significantly delayed the progress of motor dysfunction.

According to Prof. Offen, this is a uniquely successful method for differentiating bone marrow stem cells into astrocyte-like cells without manipulating the genetic material of the cell itself. They are the first team of researchers to demonstrate the efficacy of this technology in vivo in various models of neurodegenerative diseases.

The technology was licensed to BrainStorm Cell Therapeutics that has developed it into a clinical grade product called NurOwn, which is now being used in a clinical trial at Jerusalem's Hadassah Medical Center. BrainStorm Cell Therapeutics has recently struck an agreement to expand clinical trials to Massachusetts General Hospital in collaboration with the University of Massachusetts Medical School.

Home-grown therapy and talent

The ongoing clinical studies are aimed at evaluating the safety and the efficacy of this treatment, says Prof. Offen. Because the original cells are drawn from the patients themselves, he adds, the body should have no adverse reactions.

Although the current study targets ALS, these cells have the potential to treat a broad range of neurodegenerative conditions, including Parkinson's and Huntington's diseases. For many conditions, explains Prof. Offen, the current available treatments only attempt to alleviate the symptoms of these diseases rather than repair existing damage.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert

Related biology news :

1. New data from studies bolsters case for using aldosterone antagonists in heart failure
2. A 3-D reconstructed image of neural dendritic trees using the advanced electron microscope technology
3. Using a mathematical model to evaluate microsatellite genotyping from low-quality DNA
4. Lack of free play among children is causing harm, say experts in American Journal of Play
5. UC Davis researchers find disease-causing fat cells in those with metabolic syndrome
6. Using a systems biology approach to look under the hood of an aggressive form of breast cancer
7. BUSM awarded $9 million to investigate treatment for sickle cell disease using iPS cells
8. For the first time, the European IVF Monitoring Group reports on cycles using frozen eggs
9. Using DNA in fight against illegal logging
10. Using olive oil in your diet may prevent a stroke
11. Using living cells as an invisibility cloak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Research and Markets has announced the addition of ... their offering. The report forecasts ... grow at a CAGR of 12.28% during the period 2016-2020. ... market analysis with inputs from industry experts. The report covers the ... report also includes a discussion of the key vendors operating in ...
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology: